SEC FORM 4

SEC FORM 4 SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Alleva Lawrence M

(Last)

(First)

(Middle)

C/O MERSANA THERAPEUTICS, INC.

840 MEMORIAL DRIVE

(Street)

CAMBRIDGE

02139

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Mersana Therapeutics, Inc. [ MRSN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	01/06/2026		U⁽¹⁾⁽²⁾		578	D	⁽¹⁾⁽²⁾	0	D
Common Stock	01/06/2026		U⁽¹⁾⁽²⁾		84	D	⁽¹⁾⁽²⁾	0	I	See Footnote⁽⁵⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (right to buy)	$9.0775	01/06/2026		D			2,460	⁽³⁾	⁽³⁾	Common Stock	2,460	⁽³⁾	0	D
Stock Option (right to buy)	$437.5	01/06/2026		D			800	⁽⁴⁾	⁽⁴⁾	Common Stock	800	⁽⁴⁾	0	D
Stock Option (right to buy)	$434.75	01/06/2026		D			142	⁽⁴⁾	⁽⁴⁾	Common Stock	142	⁽⁴⁾	0	D
Stock Option (right to buy)	$306.75	01/06/2026		D			400	⁽⁴⁾	⁽⁴⁾	Common Stock	400	⁽⁴⁾	0	D
Stock Option (right to buy)	$107.75	01/06/2026		D			544	⁽⁴⁾	⁽⁴⁾	Common Stock	544	⁽⁴⁾	0	D
Stock Option (right to buy)	$107.75	01/06/2026		D			1,000	⁽⁴⁾	⁽⁴⁾	Common Stock	1,000	⁽⁴⁾	0	D
Stock Option (right to buy)	$134	01/06/2026		D			450	⁽⁴⁾	⁽⁴⁾	Common Stock	450	⁽⁴⁾	0	D
Stock Option (right to buy)	$572.5	01/06/2026		D			368	⁽⁴⁾	⁽⁴⁾	Common Stock	368	⁽⁴⁾	0	D
Stock Option (right to buy)	$527.25	01/06/2026		D			133	⁽⁴⁾	⁽⁴⁾	Common Stock	133	⁽⁴⁾	0	D
Stock Option (right to buy)	$372.5	01/06/2026		D			1,002	⁽⁴⁾	⁽⁴⁾	Common Stock	1,002	⁽⁴⁾	0	D
Stock Option (right to buy)	$161	01/06/2026		D			546	⁽⁴⁾	⁽⁴⁾	Common Stock	546	⁽⁴⁾	0	D
Stock Option (right to buy)	$90.5	01/06/2026		D			1,800	⁽⁴⁾	⁽⁴⁾	Common Stock	1,800	⁽⁴⁾	0	D
Stock Option (right to buy)	$106.25	01/06/2026		D			181	⁽⁴⁾	⁽⁴⁾	Common Stock	181	⁽⁴⁾	0	D
Stock Option (right to buy)	$216	01/06/2026		D			734	⁽⁴⁾	⁽⁴⁾	Common Stock	734	⁽⁴⁾	0	D
Stock Option (right to buy)	$85.5	01/06/2026		D			215	⁽⁴⁾	⁽⁴⁾	Common Stock	215	⁽⁴⁾	0	D
Stock Option (right to buy)	$31.5	01/06/2026		D			561	⁽⁴⁾	⁽⁴⁾	Common Stock	561	⁽⁴⁾	0	D
Stock Option (right to buy)	$56.75	01/06/2026		D			310	⁽⁴⁾	⁽⁴⁾	Common Stock	310	⁽⁴⁾	0	D
Stock Option (right to buy)	$110.5	01/06/2026		D			159	⁽⁴⁾	⁽⁴⁾	Common Stock	159	⁽⁴⁾	0	D
Stock Option (right to buy)	$56.5	01/06/2026		D			2,200	⁽⁴⁾	⁽⁴⁾	Common Stock	2,200	⁽⁴⁾	0	D
Stock Option (right to buy)	$49.25	01/06/2026		D			358	⁽⁴⁾	⁽⁴⁾	Common Stock	358	⁽⁴⁾	0	D
Stock Option (right to buy)	$45.75	01/06/2026		D			384	⁽⁴⁾	⁽⁴⁾	Common Stock	384	⁽⁴⁾	0	D
Stock Option (right to buy)	$35	01/06/2026		D			500	⁽⁴⁾	⁽⁴⁾	Common Stock	500	⁽⁴⁾	0	D

Explanation of Responses:

1. Pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), by and among the Issuer, Day One Biopharmaceuticals, Inc. ("Parent") and Parent's direct wholly-owned subsidiary, Emerald Merger Sub, Inc. ("Purchaser"), dated as of November 12, 2025, the shares (the "Shares") of common stock, par value $0.0001 per share, of the Issuer (the "Common Stock") that were tendered to Purchaser prior to the expiration time of the Offer were exchanged for: (i) $25.00 per Share, net to the stockholder in cash, without interest and less any applicable tax withholding (the "Upfront Cash Consideration"), plus (ii) one non-tradeable contingent value right per Share (each, a "CVR"),

2. (continued from footnote 1) which represents the right to receive certain contingent milestone payments of up to an aggregate of $30.25 per CVR in cash, without interest and less any applicable tax withholding, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a contingent value rights agreement entered into by Parent and the rights agent (the Upfront Cash Consideration plus one CVR, collectively, the "Offer Price"). After completion of the tender offer, pursuant to the terms of the Merger Agreement, Purchaser merged with and into the Issuer, effective as of January 6, 2026 (the "Effective Time"), with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent.

3. Pursuant to the terms of the Merger Agreement, effective as of immediately prior to the Effective Time, each option to purchase shares of Common Stock ("Issuer Option") that was outstanding and unexercised as of immediately prior to the Effective Time and had an exercise price per Share that was less than the Upfront Cash Consideration (each, a "Cash-Out Option"), became fully vested and was automatically cancelled and converted into the right to receive, without interest and subject to deduction for any required tax withholding, (i) the Offer Price minus (ii) the exercise price payable per share of Common Stock underlying such Cash-Out Option.

4. Pursuant to the terms of the Merger Agreement, effective as of 10 business days prior to the closing of the Merger (the "Acceleration Date"), each Issuer Option then outstanding and unexercised that had an exercise price per Share that was equal to or greater than the Upfront Cash Consideration (each, an "OTM Option"), became fully vested and exercisable up to and through the closing of regular trading on the Nasdaq Stock Market on the fifth business day following the Acceleration Date (the "Last Exercise Date"). OTM Options not exercised on or prior to the Last Exercise Date were cancelled and ceased to exist as of the Effective Time, and no consideration was delivered in exchange for such OTM Option.

5. The securities were held directly by the Lawrence M. Alleva Revocable Trust.

	/s/ Lawrence Alleva	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Director Alleva Lawrence M closing all direct ownership in the company (SEC Form 4)